ArticlePloS one2018
Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 70 citations in OpenAlex.
- The Role of Viral Dynamics and Infectivity in Models of Oncolytic Virotherapy for Tumours with Different Motility.Bulletin of mathematical biology · 2026Article
- Spatially structured models of viral dynamics: a scoping review.Microbiology and molecular biology reviews : MMBR · 2025Article
- Review
- CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma.Mathematical biosciences · 2025Article
- Long-time behavior of solutions to free boundary problems modeling tumor evolution.Applicable analysis · 2025Article
- Mesenchymal stem cell origin contributes to the antitumor effect of oncolytic virus carriers.Molecular therapy. Oncology · 2024Article
- Effects of virus-induced immunogenic cues on oncolytic virotherapy.Scientific reports · 2024Article
- Article
- Mathematical model of MMC chemotherapy for non-invasive bladder cancer treatment.Frontiers in oncology · 2024Article
- Article
- Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model.PloS one · 2022Article
- Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.PloS one · 2022Article
- Uses of Bacteriophages as Bacterial Control Tools and Environmental Safety Indicators.Frontiers in microbiology · 2021Review
- Kinetics of Oncolytic Reovirus T3D Replication and Growth Pattern in Mesenchymal Stem Cells.Cell journal · 2020Article
- Analysis of a mathematical model of rheumatoid arthritis.Journal of mathematical biology · 2020Article
- Article
- Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer.Cancers · 2019Review
- Spatial Model for Oncolytic Virotherapy with Lytic Cycle Delay.Bulletin of mathematical biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic virus (OV) is a replication competent virus that selectively invades cancer cells; as these cells die under the viral burden, the released virus particles proceed to infect other cancer cells. Oncolytic viruses are designed to also be able to stimulate the anticancer immune response. Thus, one may represent an OV by two parameters: its replication potential and its immunogenicity. In this paper we consider a combination therapy with OV and a checkpoint inhibitor, anti-PD-1. We evaluate the efficacy of the combination therapy in terms of the tumor volume at some later time, for example, 6 months from initial treatment. Since T cells kill not only virus-free cancer cells but also virus-infected cancer cells, the following question arises: Does increasing the amount of the checkpoint inhibitor always improve the efficacy? We address this question, by a mathematical model consisting of a system of partial differential equations. We use the model to construct, by simulations, an efficacy map in terms of the doses of the checkpoint inhibitor and the OV injection. We show that there are regions in the map where an increase in the checkpoint inhibitor actually decreases the efficacy of the treatment. We also construct efficacy maps with checkpoint inhibitor vs. the replication potential of the virus that show the same antagonism, namely, an increase in the checkpoint inhibitor may actually decrease the efficacy. These results have implications for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.